Biotech Values

[puravida]

Verrica Pharmaceuticals Achieves Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with Common Warts

51% of subjects in Cohort 2 achieved complete clearance of all treatable warts

VP-102 was well-tolerated with no serious adverse events reported

Common warts affect approximately 22 million people in the United States

Based on positive outcome, Verrica to request an ‘End of Phase 2’ meeting with the FDA

Management to host webcast and conference call tomorrow at 8 a.m. ET

https://investors.verrica.com/news-releases/news-release-details/verrica-pharmaceuticals-achieves-positive-topline-results-phase